| Name | Title | Contact Details |
|---|
Greenberg Sales Co is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Lantis Laser Inc is a Denville, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Lasering USA is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Community Network Services, Inc. (CNS) is a private non-profit human services agency that provides comprehensive behavioral health services. CNS offers a wide spectrum of community-based support services delivered by peer support specialists, psychiatrists, physicians assistants, nurse practitioners, and bachelor and master-level counselors and psychologists. CNS’ services assist consumers with managing their mental illness and gaining maximum independence toward self-worth and recovery. CNS provides social services supports for all aspects of consumers’ lives, reaching well beyond psychiatric or psychotherapeutic interventions.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.